LRRK2 is reduced in Parkinson’s disease gut

被引：0
|
作者：
Adrien de Guilhem de Lataillade
Jérémy Verchere
Thibauld Oullier
Alice Prigent
Tony Durand
Carolina Pellegrini
Michel Neunlist
Thierry Baron
Malvyne Rolli-Derkinderen
Pascal Derkinderen
机构：
[1] Université de Nantes,Department of Neurology
[2] Inserm,French Agency for Food, Environmental, and Occupational Health and Safety (ANSES)
[3] TENS,Department of Pharmacy
[4] The Enteric Nervous System in Gut and Brain Diseases,undefined
[5] IMAD,undefined
[6] CHU Nantes,undefined
[7] Inserm U1235 Nantes,undefined
[8] University of Lyon,undefined
[9] University of Pisa,undefined
来源：
Acta Neuropathologica | 2021年 / 142卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：601 / 603
页数：2
相关论文
共 50 条
  • [41] LRRK2 and neuroinflammation: partners in crime in Parkinson's disease?
    Russo, Isabella
    Bubacco, Luigi
    Greggio, Elisa
    JOURNAL OF NEUROINFLAMMATION, 2014, 11
  • [42] LRRK2 Inhibitors as Promising Treatment for Parkinson's Disease
    Tan, Shuoyan
    Liu, Huanxiang
    Yao, Xiaojun
    ACS CHEMICAL NEUROSCIENCE, 2024, 15 (22): : 4092 - 4094
  • [43] LRRK2 in Parkinson's disease: building an understanding of disease etiology
    Braithwaite, Steven P.
    FEBS JOURNAL, 2009, 276 (22) : 6427 - 6427
  • [44] LRRK2 mutations and Parkinson's disease in the Uruguayan population
    Raggio, V. E.
    Dieguez, E.
    Lescano, A.
    Aguiar, B.
    Aljanati, R.
    Martinovic, M.
    Amorin, I.
    Gonzalez, N.
    Ojeda, A. J.
    Pomar, V.
    Nogueira, G.
    Aguerre, L.
    Montado, G.
    Etchandi, G.
    Segredo, E.
    Soler, A. M.
    Yearout, D.
    Huston, H.
    Buzo, R.
    Zabetian, C. P.
    Mata, I. F.
    MOVEMENT DISORDERS, 2013, 28 : S399 - S399
  • [45] Common LRRK2 mutation in idiopathic Parkinson's disease
    Gilks, WP
    Abou-Sleiman, PM
    Gandhi, S
    Jain, S
    Singleton, A
    Lees, AJ
    Shaw, K
    Bhatia, KP
    Bonifati, V
    Quinn, NP
    Lynch, J
    Healy, DG
    Holton, JL
    Revesz, T
    Wood, NW
    LANCET, 2005, 365 (9457): : 415 - 416
  • [46] The Therapeutic Potential of LRRK2 and α-Synuclein in Parkinson's Disease
    Sen, Saurabh
    West, Andrew B.
    ANTIOXIDANTS & REDOX SIGNALING, 2009, 11 (09) : 2167 - 2187
  • [47] Genetic Variants of LRRK2 in Taiwanese Parkinson's Disease
    Wu, Yih-Ru
    Chang, Kuo-Hsuan
    Chang, Wen-Teng
    Hsiao, Ya-Chin
    Hsu, Hsuan-Chu
    Jiang, Pei-Ru
    Chen, Yi-Chun
    Chao, Chih-Ying
    Chang, Yi-Chung
    Lee, Bo-Hsun
    Hu, Fen-Ju
    Chen, Wan-Ling
    Lee-Chen, Guey-Jen
    Chen, Chiung-Mei
    PLOS ONE, 2013, 8 (12):
  • [48] The Upshot of LRRK2 Inhibition to Parkinson's Disease Paradigm
    Esteves, A. R.
    G-Fernandes, M.
    Santos, D.
    Januario, C.
    Cardoso, S. M.
    MOLECULAR NEUROBIOLOGY, 2015, 52 (03) : 1804 - 1820
  • [49] LRRK2 contributes to monocyte dysregulation in Parkinson’s disease
    Corinna Bliederhaeuser
    Lisa Zondler
    Veselin Grozdanov
    Wolfgang P. Ruf
    David Brenner
    Heather L. Melrose
    Peter Bauer
    Albert C. Ludolph
    Frank Gillardon
    Jan Kassubek
    Jochen H. Weishaupt
    Karin M. Danzer
    Acta Neuropathologica Communications, 4
  • [50] LRRK2 and the new era of Parkinson's disease research
    不详
    LANCET NEUROLOGY, 2016, 15 (12): : 1195 - 1195
12345